{"id":"W3007983591","doi":"10.1200/jco.2020.38.6_suppl.633","title":"Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University; University of Ottawa; Sunnybrook Hospital; University Health Network; Ottawa Hospital; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; University of Manitoba; BC Cancer Agency; Hôtel-Dieu de Québec; Université Laval; Centre Hospitalier de l’Université de Montréal; University of Alberta; Dalhousie University","funders":"","keywords":"Medicine; Discontinuation; Ipilimumab; Tolerability; Nivolumab; Internal medicine; Renal cell carcinoma; Cohort; Hazard ratio; Adverse effect; Cancer; Surgery; Oncology; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287373,0.0001957223,0.0003833152,0.001092962,0.0004561642,0.0009028091,0.0005845281,0.0003620459,0.001337198],"category_scores_gemma":[0.00420225,0.0001482487,0.0004874455,0.003688633,0.0002384414,0.0003431514,0.0004865482,0.0003950982,0.0002634324],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007229176,"about_ca_system_score_gemma":0.005666428,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5989957,"about_ca_topic_score_gemma":0.6414636,"domain_scores_codex":[0.9985859,0.0001467049,0.0001783914,0.0002275385,0.0006888159,0.0001726537],"domain_scores_gemma":[0.9943631,0.0006132583,0.002896107,0.0002218868,0.001361269,0.0005444112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001154829,0.00006512638,0.9842367,0.000214416,0.0002047141,0.00004422568,0.0001313464,0.0004209212,0.0001783089,0.00003558317,0.002513787,0.01080014],"study_design_scores_gemma":[0.00007918084,0.0002166225,0.9963665,0.0000404987,0.0001205205,0.0000945175,0.0001016708,0.0004277679,0.0001527687,0.00001203363,0.002376671,0.0000111835],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9375482,0.00194983,0.0001310029,0.0002310814,0.000007170063,0.0001084306,0.0582207,0.00002469437,0.001778968],"genre_scores_gemma":[0.9745676,0.0005943088,0.0001801151,0.00009748639,0.000009616085,0.00003944396,0.02419999,0.000006368841,0.0003051292],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4010043,"threshold_uncertainty_score":0.8067318,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1180364585338059,"score_gpt":0.3710602517689671,"score_spread":0.2530237932351612,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}